Pain is a frequently observed non-motor symptom of patients with Parkinson's disease. In some patients, Parkinson's-related pain responds to dopaminergic treatment. In the present study, we aimed to elucidate whether subthalamic deep brain stimulation has a similar beneficial effect on pain in Parkinson's disease, and whether this effect can be predicted by a pre-operative L-dopa challenge test assessing pain severity. We prospectively analyzed 14 consecutive Parkinson's patients with severe pain who underwent subthalamic deep brain stimulation. In 8 of these patients, pain severity decreased markedly with high doses of L-dopa, irrespective of the type and localization of the pain symptoms. In these patients, subthalamic deep brain stimulation provided an even higher reduction of pain severity than did dopaminergic treatment, and the majority of this group was pain-free after surgery. This effect lasted for up to 41 months. In the remaining 6 patients, pain was not improved by dopaminergic treatment nor by deep brain stimulation. Thus, we conclude that pain relief following subthalamic deep brain stimulation is superior to that following dopaminergic treatment, and that the response of pain symptoms to deep brain stimulation can be predicted by L-dopa challenge tests assessing pain severity. This diagnostic procedure could contribute to the decision on whether or not a Parkinson's patient with severe pain should undergo deep brain stimulation for potential pain relief. Ó
Introduction
Pain is a frequently observed and often burdensome non-motor symptom in Parkinson's disease (PD). Pain management is therefore an important concern in the treatment of PD patients. In some patients, pain fluctuates in parallel with motor symptoms and responds well to dopaminergic treatment [3] . Recently, pain types in PD were classified as follows: musculoskeletal, dystonic, neuropathic/radicular, primary/central, and akathisia-related [3, 5] . Recent studies with follow-up times up to 24 months revealed that deep brain stimulation (DBS) in the subthalamic nucleus (STN) improves pain in PD [4,6-8]. So far, however, it remains unclear whether or not pain responsiveness to L-dopa is an appropriate predictor for surgical outcome regarding pain relief, and whether dopaminergic medication and DBS in the STN are equally efficacious for the treatment of PD-related pain. To gain further insights into these questions, we prospectively examined the surgical outcome of 8 PD patients who suffered from severe L-dopa responsive pain, and of 6 PD patients in whom severe pain was not ameliorated by L-dopa.
Methods
We selected all consecutive PD patients who underwent STN-DBS in our movement disorders center and suffered from severe, chronic (present for more than 6 months) and persistent (daily) pain, irrespective of its type or localization. Pain was evaluated during a standardized structured interview on motor and non-motor symptoms of PD, and classified according to its phenomenology along previous recommendations [3, 5] . Of 46 operated PD patients since 2009, we identified 14 patients who suffered from severe pain, which was defined as an intensity of pain P7 as assessed using an ordinal scale ranging from 0 to 10 (0 = absent, 10 = maximal pain). These patients suffered from different types of pain (Table 1) . DBS was performed because of PD-associated motor fluctuations that were not adequately controlled with oral dopaminergic medication. This study was approved by the local ethical committee.
